Valuation: Rakovina Therapeutics Inc.

Market Cap 6.98M 7.82M 6.52M 5.92M 11.15M 756M 11.23M 78.3M 30.59M 385M 29.35M 28.71M 1.24B P/E 2026 *
-25x
P/E 2027 * -25x
Enterprise Value 7.55M 8.45M 7.04M 6.39M 12.04M 817M 12.13M 84.6M 33.05M 415M 31.71M 31.02M 1.34B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day+9.31%
1 week+9.31%
Current month+9.31%
1 month+24.11%
3 months+104.87%
6 months+169.23%
Current year+152.96%
1 week 0.19
Extreme 0.1882
0.19
1 month 0.13
Extreme 0.1321
0.2
Current year 0.04
Extreme 0.0404
0.2
1 year 0.04
Extreme 0.0404
0.22
3 years 0.04
Extreme 0.0404
100
5 years 0.04
Extreme 0.0404
100
10 years 0.04
Extreme 0.0404
100
Manager TitleAgeSince
Chief Executive Officer 62 2026-01-26
Director of Finance/CFO - 2025-04-30
President - 2020-12-31
Director TitleAgeSince
Chairman 58 2020-11-30
Director/Board Member 69 2026-01-26
Director/Board Member 62 2026-01-26
Change 5-day change 1-year change 3-year change Capi.($)
+9.31%+9.31% - - 7.84M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.34% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
+0.50%-2.14%+331.33%+702.20% 42.84B
-0.72%-3.99%+28.50%+29.94% 42.79B
+0.34%-0.52%+6.56%+109.35% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
-0.50%-3.10%-10.19%-14.35% 24.05B
Average +1.15%-0.32%+53.35%+123.79% 43.81B
Weighted average by Cap. +0.69%-0.61%+56.27%+130.20%

Financials

2026 *2027 *
Net sales - -
Net income -4.26M -4.77M -3.97M -3.61M -6.8M -461M -6.85M -47.74M -18.65M -234M -17.89M -17.5M -754M -4.56M -5.1M -4.25M -3.86M -7.27M -493M -7.32M -51.07M -19.95M -251M -19.14M -18.73M -806M
Net Debt 562K 629K 524K 476K 896K 60.8M 903K 6.3M 2.46M 30.92M 2.36M 2.31M 99.41M 1.53M 1.71M 1.43M 1.3M 2.44M 165M 2.46M 17.14M 6.69M 84.16M 6.42M 6.28M 271M
Projected Income Statement - Annual - Rakovina Therapeutics Inc.
Logo Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. It is focused on the development of cancer treatments based on deoxyribonucleic acid (DNA)-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking and Enki platforms. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.
Employees
-
Date Price Change Volume
26-10-05 US$0.1925 +9.31% 2,250
26-09-30 US$0.1761 -4.66% 36,625
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.2500CAD
Average target price
0.2500CAD
Spread / Average Target
0.00%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Rakovina Therapeutics Inc.